Cassava Sciences Competitors

Sarepta Therapeutics (NASDAQ:SRPT) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Volatility & Risk

Sarepta Therapeutics has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sarepta Therapeutics and Cassava Sciences, as provided by MarketBeat.com.

Sarepta Therapeutics presently has a consensus target price of $150.4762, indicating a potential upside of 104.84%. Cassava Sciences has a consensus target price of $35.3333, indicating a potential downside of 0.86%. Given Sarepta Therapeutics' higher probable upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Cassava Sciences.

Insider & Institutional Ownership

89.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 13.7% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Sarepta Therapeutics and Cassava Sciences' revenue, earnings per share (EPS) and valuation.

Cassava Sciences has lower revenue, but higher earnings than Sarepta Therapeutics. Cassava Sciences is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sarepta Therapeutics and Cassava Sciences' net margins, return on equity and return on assets.

Summary

Cassava Sciences beats Sarepta Therapeutics on 7 of the 13 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Insider and Institutional Ownership

65.4% of Allakos shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 44.8% of Allakos shares are held by company insiders. Comparatively, 13.7% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Allakos and Cassava Sciences, as reported by MarketBeat.com.

Allakos presently has a consensus target price of $181.50, indicating a potential upside of 68.96%. Cassava Sciences has a consensus target price of $35.3333, indicating a potential downside of 0.86%. Given Allakos' higher probable upside, equities research analysts clearly believe Allakos is more favorable than Cassava Sciences.

Valuation and Earnings

This table compares Allakos and Cassava Sciences' top-line revenue, earnings per share (EPS) and valuation.

Cassava Sciences is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Allakos has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Allakos and Cassava Sciences' net margins, return on equity and return on assets.

Summary

Cassava Sciences beats Allakos on 5 of the 9 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Risk and Volatility

Blueprint Medicines has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Earnings & Valuation

This table compares Blueprint Medicines and Cassava Sciences' revenue, earnings per share (EPS) and valuation.

Cassava Sciences has lower revenue, but higher earnings than Blueprint Medicines. Cassava Sciences is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Blueprint Medicines and Cassava Sciences, as reported by MarketBeat.

Blueprint Medicines presently has a consensus price target of $112.40, indicating a potential upside of 16.03%. Cassava Sciences has a consensus price target of $35.3333, indicating a potential downside of 0.86%. Given Blueprint Medicines' higher possible upside, research analysts plainly believe Blueprint Medicines is more favorable than Cassava Sciences.

Profitability

This table compares Blueprint Medicines and Cassava Sciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

26.7% of Cassava Sciences shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Comparatively, 13.7% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Blueprint Medicines beats Cassava Sciences on 8 of the 14 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings for Perrigo and Cassava Sciences, as provided by MarketBeat.

Perrigo presently has a consensus price target of $52.00, suggesting a potential upside of 28.68%. Cassava Sciences has a consensus price target of $35.3333, suggesting a potential downside of 0.86%. Given Perrigo's higher probable upside, equities analysts clearly believe Perrigo is more favorable than Cassava Sciences.

Earnings & Valuation

This table compares Perrigo and Cassava Sciences' top-line revenue, earnings per share and valuation.

Perrigo has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.7% of Perrigo shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 0.3% of Perrigo shares are held by insiders. Comparatively, 13.7% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Perrigo has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Perrigo and Cassava Sciences' net margins, return on equity and return on assets.

Summary

Perrigo beats Cassava Sciences on 7 of the 13 factors compared between the two stocks.

Cassava Sciences (NASDAQ:SAVA) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Insider & Institutional Ownership

26.7% of Cassava Sciences shares are owned by institutional investors. Comparatively, 41.3% of Schrödinger shares are owned by institutional investors. 13.7% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Cassava Sciences and Schrödinger, as provided by MarketBeat.

Cassava Sciences currently has a consensus price target of $35.3333, suggesting a potential downside of 0.86%. Schrödinger has a consensus price target of $85.50, suggesting a potential upside of 9.69%. Given Schrödinger's higher probable upside, analysts clearly believe Schrödinger is more favorable than Cassava Sciences.

Valuation & Earnings

This table compares Cassava Sciences and Schrödinger's revenue, earnings per share (EPS) and valuation.

Cassava Sciences has higher earnings, but lower revenue than Schrödinger.

Profitability

This table compares Cassava Sciences and Schrödinger's net margins, return on equity and return on assets.

Galapagos (NASDAQ:GLPG) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Risk & Volatility

Galapagos has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Galapagos and Cassava Sciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Galapagos and Cassava Sciences' gross revenue, earnings per share and valuation.

Galapagos has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.2% of Galapagos shares are owned by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 13.7% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Galapagos and Cassava Sciences, as reported by MarketBeat.com.

Galapagos currently has a consensus target price of $143.7273, indicating a potential upside of 78.54%. Cassava Sciences has a consensus target price of $35.3333, indicating a potential downside of 0.86%. Given Galapagos' higher possible upside, equities analysts clearly believe Galapagos is more favorable than Cassava Sciences.

Summary

Galapagos beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.